This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The global wellness market is valued at more than US $ 1.5 trillion, with annual growth of 5-10 per cent
The aspirant can enrol in MBA (Healthcare and Hospital Management) at Ganpat University, -Centre for Management Studies and Research, which will be facilitated by Ganpat University and Shalby Centre for Healthcare Management and Research
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
Klifovet’s client base comprises the world’s top animal health and nutrition companies as well as many promising startups
Subscribe To Our Newsletter & Stay Updated
